With an FDA verdict looming, GSK has signed an eleventh-hour deal to give Alfasigma rights to its primary biliary cholangitis therapy linerixibat.
FDA seeks to encourage fewer animal studies with new draft guidance
The FDA unveiled long-awaited draft guidance on how biopharma companies can validate new approaches for toxicology and other early-phase safety studies, potentially reducing the animal

